中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

28 records (took 0.019 seconds)

    Pharmaceutical compositions of rifaximin
    23.
    发明授权
    Pharmaceutical compositions of rifaximin 有权
    利福昔明的药物组合物

    公开(公告)号：US08383151B2

    公开(公告)日：2013-02-26

    申请号：US12144453

    申请日：2008-06-23

    Applicant: Harshal Anil Jahagirdar ,  Rajesh Kulkarni ,  Shirishkumar Kulkarni

    Inventor： Harshal Anil Jahagirdar ,  Rajesh Kulkarni ,  Shirishkumar Kulkarni

    IPC: A61K9/20

    CPC classification number: A61K31/44 ,  A61K9/1623 ,  A61K9/1652 ,  A61K9/2086 ,  A61K9/2846 ,  A61K9/2866 ,  A61K9/4808 ,  Y02A50/473 ,  Y02A50/475

    Abstract: A pharmaceutical composition comprising therapeutically effective amount of rifaximin or pharmaceutically acceptable salt or enantiomer or polymorph thereof, pharmaceutically acceptable excipient(s) and release controlling agent(s). Pharmaceutical composition of rifaximin comprising: at least two entities wherein one entity is an immediate release or fast release and the other is controlled release. The pharmaceutical composition in the form of multilayer tablet comprising, at least one layer comprising, therapeutically effective amount of rifaximin or pharmaceutically acceptable salt or enantiomer or polymorph thereof, pharmaceutically acceptable excipient(s); said layer providing controlled release rifaximin; and at least one layer which provides increased residence time of the dosage form in the gastrointestinal tract. The pharmaceutical formulation comprising rifaximin having an in vitro dissolution profile, wherein about 70% of rifaximin is released in about 24 hours. The composition comprising therapeutically effective amount of rifaximin or pharmaceutically acceptable salt(s) or enantiomer(s) or polymorph(s) thereof, one or more release controlling agent(s) and pharmaceutically acceptable excipient(s) causing pathogenic eradication.

    Abstract translation: 一种药物组合物，其包含治疗有效量的利福昔明或其药学上可接受的盐或对映异构体或其多晶型物，药学上可接受的赋形剂和释放控制剂。 利福昔明的药物组合物包括：至少两个实体，其中一个实体是立即释放或快速释放，另一个实体是控制释放的。 多层片剂形式的药物组合物，包含至少一层，其包含治疗有效量的利福昔明或其药学上可接受的盐或对映体或其多晶型物，药学上可接受的赋形剂; 所述层提供受控释放的利福昔明; 以及提供剂型在胃肠道中的延长停留时间的至少一个层。 包含具有体外溶出曲线的利福昔明的药物制剂，其中约70％的利福昔明在约24小时内释放。 所述组合物包含治疗有效量的利福昔明或其药学上可接受的盐或对映异构体或多晶型物，一种或多种释放控制剂和引起致病根除的药学上可接受的赋形剂。

    ORAL COMPOSITIONS OF CLINDAMYCIN
    26.
    发明申请
    ORAL COMPOSITIONS OF CLINDAMYCIN 有权
    CLINDAMYCIN口服组合物

    公开(公告)号：US20110123631A1

    公开(公告)日：2011-05-26

    申请号：US13055004

    申请日：2008-09-10

    Applicant: Kalpana Walzade ,  Rajesh Kulkarni ,  Shirishkumar Kulkarni

    Inventor： Kalpana Walzade ,  Rajesh Kulkarni ,  Shirishkumar Kulkarni

    IPC: A61K31/7056 ,  A61K9/14 ,  A61K9/50 ,  A61P31/04 ,  A61P33/02 ,  A61P33/06

    CPC classification number: A61K9/0095 ,  A61K9/1623 ,  A61K9/1641 ,  A61K9/5026 ,  Y02A50/411

    Abstract: A taste masked pharmaceutical composition of clindamycin, or a pharmaceutically acceptable salt(s), hydrate(s), solvate(s) and physiologically functional derivative(s) and precursors thereof, which includes all polymorphic forms, whether crystalline or amorphous comprising polyhydric alcohol(s); and one or more other pharmaceutically acceptable excipient(s). A process for preparation of a taste masked pharmaceutical composition of clindamycin or a pharmaceutically acceptable salt(s) thereof the said process comprising the steps of a) dry mixing clindamycin, polyhydric alcohol and other pharmaceutically acceptable excipient(s) to get a dry mixture; b) granulating the dry mixture above with a granulating liquid prepared by mixing the suitable pharmaceutically acceptable excipient(s) with aqueous/non-aqueous fluid to obtain a wet mass; c) drying the wet mass to obtain the discrete particles; d) lubricating the discrete particles obtained with a suitable lubricating agent and/or flavour(s).

    Abstract translation: 克林霉素或其药学上可接受的盐，水合物，溶剂合物和生理功能衍生物及其前体的掩味药物组合物，其包括所有多晶型物，无论是多晶型还是含有多元醇的无定形物质 （s）; 和一种或多种其它药学上可接受的赋形剂。 制备克林霉素或其药学上可接受的盐的掩味药物组合物的方法，所述方法包括以下步骤：a）将克林霉素，多元醇和其它药学上可接受的赋形剂干混以得到干混合物; b）将上述干混合物用通过将合适的药学上可接受的赋形剂与水/非水性流体混合而制备的造粒液体制粒以获得湿质量; c）干燥湿物质以获得离散颗粒; d）润滑用合适的润滑剂和/或风味获得的离散颗粒。

    PHARMACEUTICAL COMPOSITIONS FOR GASTROINTESTINAL DRUG DELIVERY
    28.
    发明申请
    PHARMACEUTICAL COMPOSITIONS FOR GASTROINTESTINAL DRUG DELIVERY 有权
    用于胃肠道给药的药物组合物

    公开(公告)号：US20090011019A1

    公开(公告)日：2009-01-08

    申请号：US12144894

    申请日：2008-06-24

    Applicant: Harshal Anil Jahagirdar ,  Rajesh Kulkarni ,  Shirishkumar Kulkarni

    Inventor： Harshal Anil Jahagirdar ,  Rajesh Kulkarni ,  Shirishkumar Kulkarni

    IPC: A61K9/24 ,  A61K9/20

    CPC classification number: A61K47/44 ,  A61K9/0065 ,  A61K9/0095 ,  A61K9/1611 ,  A61K9/1617 ,  A61K9/1623 ,  A61K9/1635 ,  A61K9/1641 ,  A61K9/1652 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2031 ,  A61K9/205 ,  A61K9/2054 ,  A61K9/2086 ,  A61K9/209 ,  A61K31/196 ,  A61K31/197 ,  A61K31/437 ,  A61K31/4402 ,  A61K31/606 ,  A61K31/635 ,  A61K31/655 ,  A61K31/785 ,  A61K38/12 ,  A61K47/32 ,  A61K47/34 ,  A61K47/38

    Abstract: A novel pharmaceutical composition, which comprises a therapeutically effective amount of active principle(s) or a pharmaceutically acceptable salt or enantiomer or polymorph thereof, optionally one or more release controlling agent(s) and pharmaceutical acceptable excipient(s) thereof, wherein the composition is formulated to increase the residence time of the said pharmaceutical composition and/or active principle(s) in the gastrointestinal tract. A novel pharmaceutical composition comprising at least two entities wherein one entity is an immediate release/fast release and the other is controlled release. A pharmaceutical composition comprising at least two entities wherein one entity is an immediate release/fast release and the other is bioadhesive. A pharmaceutical composition comprising: at least two entities wherein one entity is controlled release and the other is bioadhesive All the three compositions are formulated to increase the residence time of active principle(s) in the gastrointestinal tract. A multilayered composition with active in a layer which provides immediate release or controlled release of active principles and layer providing increased residence time in the GI tract.

    Abstract translation: 一种新型药物组合物，其包含治疗有效量的活性成分或其药学上可接受的盐或对映体或多晶型物，任选的一种或多种释放控制剂及其药学上可接受的赋形剂，其中所述组合物 配制成增加所述药物组合物和/或活性成分在胃肠道中的停留时间。 一种新型药物组合物，其包含至少两个实体，其中一个实体是即时释放/快速释放，另一个实体是控制释放的。 包含至少两个实体的药物组合物，其中一个实体是立即释放/快速释放，另一个是生物粘附的。 一种药物组合物，其包含：至少两个实体，其中一个实体被控制释放，另一个实体是生物粘附剂。所有三种组合物被配制以增加活性成分在胃肠道中的停留时间。 在层中具有活性的多层组合物，其提供活性成分和层的即时释放或控制释放，从而在GI道中提供增加的停留时间。

Patent Agency Ranking